
## Ryan J Watts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4776625/publications.pdf Version: 2024-02-01



RVAN I WATTS

#	Article	IF	CITATIONS
1	Molecular architecture determines brain delivery of a transferrin receptor–targeted lysosomal enzyme. Journal of Experimental Medicine, 2022, 219, .	8.5	31
2	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine, 2021, 13, .	12.4	76
3	Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell, 2021, 184, 4651-4668.e25.	28.9	97
4	Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Science Translational Medicine, 2020, 12, .	12.4	121
5	Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Science Translational Medicine, 2020, 12, .	12.4	184
6	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	8.2	105
7	Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. Journal of Biological Chemistry, 2017, 292, 3900-3908.	3.4	206
8	BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats. Scientific Reports, 2017, 7, 44249.	3.3	12
9	Widespread brain distribution and activity following i.c.v. infusion of antiâ€Î²â€secretase (BACE1) in nonhuman primates. British Journal of Pharmacology, 2017, 174, 4173-4185.	5.4	40
10	Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice. Bioanalysis, 2016, 8, 1067-1075.	1.5	5
11	Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies. Neuron, 2016, 89, 70-82.	8.1	193
12	Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 101, 53-61.	4.3	38
13	A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nature Medicine, 2014, 20, 1452-1457.	30.7	116
14	Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Science Translational Medicine, 2014, 6, 261ra154.	12.4	276
15	The Blood-Brain Barrier's Gut Check. Science Translational Medicine, 2014, 6, 263fs46.	12.4	8
16	Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. Journal of Experimental Medicine, 2014, 211, 233-244.	8.5	242
17	Bispecific antibodies for delivery into the brain. Current Opinion in Chemical Biology, 2013, 17, 393-399.	6.1	71
18	Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier. Science Translational Medicine, 2013, 5, 183ra57, 1-12.	12.4	199

RYAN J WATTS

#	Article	IF	CITATIONS
19	Developing Therapeutic Antibodies for Neurodegenerative Disease. Neurotherapeutics, 2013, 10, 459-472.	4.4	166
20	Transferrin Antibodies Into the Brain. Neuropsychopharmacology, 2012, 37, 302-303.	5.4	16
21	Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target. Science Translational Medicine, 2011, 3, 84ra44.	12.4	623
22	A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo. Science Translational Medicine, 2011, 3, 84ra43.	12.4	246
23	Engaging neuroscience to advance translational research in brain barrier biology. Nature Reviews Neuroscience, 2011, 12, 169-182.	10.2	508